24 results for “data”
A data and economics specialist working across Germany’s medical cannabis sector will join the Cannabis Health Symposium Frankfurt later this year.
Pharmacist independent prescribers accounted for 61.9% of the total items prescribed between January 2019 and May 2025.
After two years of Germany’s Cannabis Act (CanG), the most comprehensive analysis of its impact to date has been published.
Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower in 2025, a 12% increase from the prior year, according to new data obtained by Prohibition Partners. By October, monthly volumes […]
The first official evaluation of the CanG reforms highlights early trends in market growth, youth use, health outcomes, and crime.
A substantial number of patients’ details, including prescription information, were found on a file hosting website.
The issues raised have led to calls for a multi-agency review and clarification of the regulations.
In a special edition of the Business of Cannabis Podcast, we go from anecdote to evidence with Dr Anne Katrin Schlag, Head of Research at Drug Science, and Graham Woodward, Chief Operating Officer at Releaf.
A Freedom of Information request has established that the NHS will publish data from its ‘registry’ by the ‘end of the year’.
Jazz Pharmaceuticals has shared new data on Epidiolex in patients with tuberous sclerosis complex (TSC).
Patients showed improvements in sleep, anxiety and overall quality of life.
Prescribed cannabis was associated with an improvement in symptoms, quality of life and a reduction in opioid use.
The ‘groundbreaking’ digital study will help researchers learn more about rare childhood epilepsies.
Despite launching in April 2021 the NHS cannabis patient registry is yet to collect any data.
New studies highlight the effects of cannabis in those living with depression, childhood epilepsy and inflammatory bowel disease (IBD).
Patients experienced an improvement in symptoms and quality of life when prescribed cannabis.
Data was collected from the experiences of more than 200,000 cannabis consumers in the US.
The study is thought to be the largest to date examining medical cannabis for anxiety and depression
MyAccess Clinics (MAC) will now be taking on new patients through Project Twenty21.
New guidance, which appears to recognise the value of real-world evidence, has been welcomed by experts.
Cannabis legalisation led to a temporary decline in opioid-related A&E visits
These are some of the most popular CBD products purchased during the pandemic.
Thousands of patients are using medical cannabis for conditions where there is ‘debatable’ clinical evidence
New data analysis from a US-based medical cannabis platform has shone a light on how patients use the treatment. Leafwell, an online platform that helps patients access medical cannabis, looked […]
